Clinical Trial Update: Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III clinical trial evaluating neoadjuvant therapy with Pablizumab combined with Apatinib and chemotherapy in resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• Pablizumab

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN